DE60319982D1 - Universelle Zusammensetzung zur kontrollierten Wirkstofffreigabe enthaltend Xanthangummi und Natriumalginat - Google Patents

Universelle Zusammensetzung zur kontrollierten Wirkstofffreigabe enthaltend Xanthangummi und Natriumalginat

Info

Publication number
DE60319982D1
DE60319982D1 DE60319982T DE60319982T DE60319982D1 DE 60319982 D1 DE60319982 D1 DE 60319982D1 DE 60319982 T DE60319982 T DE 60319982T DE 60319982 T DE60319982 T DE 60319982T DE 60319982 D1 DE60319982 D1 DE 60319982D1
Authority
DE
Germany
Prior art keywords
sodium alginate
xanthan gum
active substance
controlled release
substance containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60319982T
Other languages
English (en)
Other versions
DE60319982T2 (de
Inventor
Adnan Ali Badwan
Mayyas Mohammad Ahma Al-Remawi
Mutaz Bellah A W Sheikh Salem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jordanian Pharmaceutical Manufacturing Co
Original Assignee
Jordanian Pharmaceutical Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jordanian Pharmaceutical Manufacturing Co filed Critical Jordanian Pharmaceutical Manufacturing Co
Publication of DE60319982D1 publication Critical patent/DE60319982D1/de
Application granted granted Critical
Publication of DE60319982T2 publication Critical patent/DE60319982T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60319982T 2003-09-01 2003-09-01 Universelle Zusammensetzung zur kontrollierten Wirkstofffreigabe enthaltend Xanthangummi und Natriumalginat Expired - Fee Related DE60319982T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03019531A EP1510205B1 (de) 2003-09-01 2003-09-01 Universelle Zusammensetzung zur kontrollierten Wirkstofffreigabe enthaltend Xanthangummi und Natriumalginat

Publications (2)

Publication Number Publication Date
DE60319982D1 true DE60319982D1 (de) 2008-05-08
DE60319982T2 DE60319982T2 (de) 2009-04-16

Family

ID=34089635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319982T Expired - Fee Related DE60319982T2 (de) 2003-09-01 2003-09-01 Universelle Zusammensetzung zur kontrollierten Wirkstofffreigabe enthaltend Xanthangummi und Natriumalginat

Country Status (5)

Country Link
US (1) US20050074491A1 (de)
EP (1) EP1510205B1 (de)
JP (1) JP2005075830A (de)
AT (1) ATE390122T1 (de)
DE (1) DE60319982T2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101612140B (zh) * 2009-07-13 2011-12-14 浙江金华康恩贝生物制药有限公司 一种双氯芬酸钾缓释微丸胶囊的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US4867970A (en) * 1987-05-21 1989-09-19 E. R. Squibb & Sons, Inc. Moistureless oral drug delivery formulation and method for preparing same
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
IN186245B (de) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
WO2002041876A1 (en) * 2000-11-22 2002-05-30 Lupin Limited Pharmaceutical composition for controlled release of an active ingredient

Also Published As

Publication number Publication date
ATE390122T1 (de) 2008-04-15
EP1510205B1 (de) 2008-03-26
JP2005075830A (ja) 2005-03-24
EP1510205A1 (de) 2005-03-02
US20050074491A1 (en) 2005-04-07
DE60319982T2 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
RU2004137118A (ru) Фармацевтическая композиция для контролируемого высвобождения активных веществ и способ ее изготовления
BRPI0409336A (pt) sistema de liberação compreendendo uma pelìcula de gel termorreversìvel, homogênea, pelìcula de sistema de liberação, e, processo para preparar o sistema de liberação da mesma
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2006123678A1 (ja) ドロキシドパを含有する安定な錠剤
WO2003074086A1 (fr) Matrice liquide a transfert de phase in vivo, et preparations liquides orales
ATE260649T1 (de) Pharmazeutische formulierung und dosierform bestehend aus polysacchariden zur kontrollierten wirkstoff-freisetzung im dickdarm
BR9913696A (pt) Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial
EA200702520A1 (ru) Составы для изменения биофизических свойств слизистой оболочки
BR0307278A (pt) Formulação oral de liberação imediata, e, método para preparar uma formulação
NO20033564D0 (no) Ny formulering med modifisert frigivningsvirkning
BRPI1007161B1 (pt) Composição farmacêutica oral sólida, e, processo para preparar uma composição
NO20092662L (no) Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme
ES2547722T3 (es) Formulación de liberación controlada para la administración oral de metformina
JP2007119552A (ja) （メタ）アクリル酸系含水ゲル体の製造方法および（メタ）アクリル酸系含水ゲル
JP2006321792A (ja) 含水ゲル体及びその製造方法
US20080119519A1 (en) Base Forming Drug-Layered Silicate Hybrid Containing Basic Polymer and its Synthesis Method
BRPI0311511B1 (pt) "preparações farmacêuticas líquidas, e sua aplicação".
DE60319983D1 (de) Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan
PT667155E (pt) Comprimidos de acido tioctico de tamanho bem definido
DE60319982D1 (de) Universelle Zusammensetzung zur kontrollierten Wirkstofffreigabe enthaltend Xanthangummi und Natriumalginat
JP4965096B2 (ja) 圧縮成型製剤
KR20080080318A (ko) 지용성 약물을 함유하는 구강내 속붕정
HU203477B (en) Process for producing antiflatulant pharmaceutical compositions containing activated poly-dimethyl-siloxane in form of solide dispersion
ATE355833T1 (de) Pharmazeutische polymerformulierung zur retardierten freisetzung von terbutalinsulfat
WO2005079753A2 (en) Extended release pharmaceutical compositions of divalproex sodium

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee